Skip to main content

Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources

Written by Customer Service on . Posted in Public Companies.

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) — Surrozen Inc. (Nasdaq: SRZN), a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway, today announced that Elizabeth “Liz” Nguyen has been appointed as Vice President and Head of Human Resources (HR). Ms. Nguyen brings over 20 years of experience in organizational design, talent recruitment, building a performance culture, planning and leadership development.

“Liz is joining Surrozen at a time of tremendous growth as we advance our two lead programs into the clinic and continue our momentum and progress on our broad research pipeline,” said Craig Parker, President and Chief Executive Officer of Surrozen. “Liz’s extensive knowledge and insight into HR strategies in the biotechnology industry will enable us to build an effective organization by growing and managing highly innovative and dynamic teams.”

Most recently, Ms. Nguyen served as the Executive Director, Head of HR Business Partnering & Interim HR Site Head of MyoKardia through its acquisition by Bristol Myers Squibb. In this capacity, she played a key role in building out HR strategies for MyoKardia during its growth from a privately held company to a publicly traded organization. Before joining MyoKardia, Ms. Nguyen was Director of Human Resources Business Partner at InterMune, serving as an HR Business Partner to more than 120 employees within the research and development organization. She also played a key role in developing and implementing HR integration strategies as part of InterMune’s merger with Roche-Genentech. She previously held leadership roles in human resources at Onyx Pharmaceuticals, MedImmune, AECOM International, Raytheon Company and ACDI/VOCA. Ms. Nguyen received her BS in Economy from Virginia Tech and a Masters in Human Resources Management from Marymount University.

“Throughout my career, I have had opportunities to lead efforts in building HR functions and programs to foster growth, development and a strong culture,” said Ms. Nguyen. “ I look forward to working with the team to continue to make Surrozen a dynamic and exciting place to work.”

About Surrozen
Surrozen is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. Surrozen is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with potential application across multiple disease areas, including inflammatory bowel disease, hepatitis, eye diseases, hearing loss, lung and airway diseases, and certain neurological disorders. For more information, please visit surrozen.com.

Forward Looking Statement

These materials may contain forward-looking statements regarding Surrozen, Inc. (the “Company”). There can be no assurance that these forward-looking statements can or will be achieved, and the Company makes no representations or warranties as to its actual future performance. In addition, the Company makes no warranties or representations regarding the accuracy or completeness of these materials and expressly disclaims any obligation to correct, update or revise any of these materials for any reason. The recipient of these materials should conduct its own investigation and analysis of the business of the Company and the data described in these materials.

Media Contact

Surabhi Verma, Account Director
CanaleComm
Tel.: (848) 250-0266
Email: Surabhi.Verma@CanaleComm.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.